News Category
Helus Pharma's appointment of Regina Donohue as Chief People Officer and Suresh Durgam to its Scientific Advisory Board underscores its commitment to ...
Helus Pharma completes enrollment in its pivotal Phase 3 APPROACH trial for HLP003 in major depressive disorder, with topline data expected in Q4 2026...
Helus Pharma's appointment of Michael Halstead as CEO, coupled with advancing Phase 3 trials, signals a strategic shift toward commercialization.
Luke Van Der Veer's Website Rental Coaching program, which teaches local SEO and the 'Rank and Rent' model, has expanded to 14 countries with 467 stud...
Ireland's new Mental Health Act bans electroconvulsive therapy (ECT) for minors, a move praised by human rights advocates but seen as insufficient as ...
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trial for HLP003, a treatment for major depressive disorder, with top...
Helus Pharma has closed a $50 million public offering to fund Phase 3 trials for HLP003 in major depressive disorder and other pipeline candidates, ad...
Helus Pharma announced the pricing of a $50 million public offering to advance its Phase 3 major depressive disorder program and other mental health t...
Helus Pharma announced that enrollment in its Phase 3 APPROACH trial for HLP003 in major depressive disorder has exceeded 86%, keeping the study on sc...
Helus Pharma's CMO will discuss the company's novel serotonergic agonists at a key industry conference, highlighting its Phase 3 depression treatment ...
Craig Munro Wilson's 'Baptize America' argues that the 1820 Campbell-Walker debate was a pivotal event that defined American Christianity's identity, ...
Helus Pharma issued a correction to its partnership announcement with TARA Mind, removing references to Veterans Exploring Treatment Solutions while r...
Helus Pharma appointed two prominent scientists to its advisory board, bolstering its expertise as it advances novel serotonergic agonists for mental ...
Helus Pharma announced the immediate resignation of CEO Michael Cola at the board's request, with co-founder Eric So stepping in as interim CEO to ens...
Helus Pharma appoints Dr. Ken Kramer, a seasoned neuroscience executive, as senior vice president of medical affairs to advance its clinical-stage ser...
The launch of the first data center in Europe operating on a microgrid marks a significant step toward sustainable and resilient digital infrastructur...
Helus Pharma's Phase 2 study shows HLP004 significantly reduces anxiety symptoms in GAD patients with limited treatment options, supporting continued ...
Helus Pharma announced the appointment of Dr. Freda Lewis-Hall, a veteran biopharmaceutical leader, to its board and as chair of its Scientific Adviso...
Helus Pharma announced that a Phase 2a trial of SPL026 for major depressive disorder met its primary endpoint with significant reductions in depressiv...
Helus Pharma's Q3 2025 financial results highlight progress in its Phase 3 major depressive disorder and Phase 2 generalized anxiety disorder programs...
Helus Pharma has appointed Michael Cola as CEO to lead the company through pivotal Phase 2 and Phase 3 data readouts for its novel serotonergic agonis...
Fully Promoted achieved year-over-year sales growth, signed 57 new franchise agreements, and expanded into India, Ireland, and Cameroon, highlighting ...
Exit Factor, a leading franchise in business value enhancement and exit planning, announces ambitious international growth plans for 2026 following a ...
